中国宏桥公告，其控股股东宏桥控股将通过配售代理向独立承配人配售其持有的股份，同时宏桥控股将 认购公司新发行的股份。 此次配售及认购的发行价为每股29.20港元，较前一交易日收盘价折让约9.60%。预计此次认购将为公司 带来约114.9亿港元的净所得款项，公司计划将这笔资金用于国内外项目发展、偿还债务以优化资本结 构，以及补充营运资金和一般企业用途。 ...

Core Viewpoint - Horizon Robotics-W (09660) has announced a placement and subscription agreement aimed at optimizing its capital structure and supporting sustainable development, with a net estimated proceeds of approximately HKD 6.339 billion [1] Group 1: Placement and Subscription Agreement - The company and existing shareholders have entered into an agreement where existing shareholders agree to sell shares at a placement price of HKD 9.99 per share [1] - The placement price represents a discount of approximately 5.75% compared to the last closing price of HKD 10.60 per share on the Stock Exchange [1] - Existing shareholders conditionally agree to subscribe for shares at the same placement price of HKD 9.99 per share [1] Group 2: Use of Proceeds - The estimated net proceeds of approximately HKD 6.339 billion will be used to optimize the company's capital structure [1] - The funds are intended to support the company's health and sustainable development initiatives [1]

Group 1 - The company Yunfeng Financial (00376) has completed a placement of shares on September 18, 2025, under the terms of the placement and subscription agreement [1] - A total of 191.3 million existing shares were successfully placed at a price of HKD 6.10 per share to no fewer than six subscribers, all of whom are independent third parties [1] - Following the completion of the subscription, the total amount raised from the subscription was approximately HKD 1.17 billion, with a net amount of approximately HKD 1.15 billion [1] Group 2 - After the completion of the placement and subscription, no subscriber has become a major shareholder of the company [1] - All conditions for the completion of the subscription have been met, leading to the issuance of 191.3 million subscription shares at the same price of HKD 6.10 per share on September 23, 2025 [1]

Core Viewpoint - 康诺亚-B (02162.HK) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 864 million for various purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing about 7.72% of the company's issued shares as of the announcement date [2]. - The subscription involves 19 million new shares, accounting for approximately 6.36% of the enlarged share capital post-placement and subscription [2]. - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from about 27.79% to approximately 25.16% of the enlarged issued share capital [2]. Group 2: Pricing and Financial Details - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10 [2]. - The total expected proceeds from the subscription are approximately HKD 864 million, with net proceeds estimated at around HKD 854 million [2]. Group 3: Use of Proceeds - The net proceeds are planned to be allocated as follows: approximately 35% for R&D expenses related to CM512, CM518D1, and other pipelines; about 30% for the commercialization of the drug Siplizumab; around 25% for capital expenditures on manufacturing and R&D facilities; and 10% for general corporate and operational purposes [2].

Core Viewpoint - 康诺亚-B (02162) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 854 million for various development and operational purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing approximately 7.72% of the company's issued shares as of the announcement date [2]. - The number of subscription shares is 19 million, accounting for about 6.36% of the expanded share capital post-placement and subscription [2]. - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10, 2025 [2]. Group 2: Use of Proceeds - The net proceeds from the subscription, estimated to be around HKD 854 million after deducting commissions and estimated expenses, will be allocated for: - Research and development expenses for CM512, CM518D1, and other pipeline projects [2]. - Commercialization of the drug Siplizumab [2]. - Capital expenditures for manufacturing and research facilities [2]. - General corporate and operational funding [2].